News

Rifampin is the generic equivalent of Rifadin capsules marketed by Sanofi Aventis US and is indicated in the treatment of all forms of tuberculosis and for the treatment

The trial is designed to evaluate the safety and efficacy of pimavanserin in approximately 240 patients with Parkinson’s disease psychosis (PDP). Patients in the trial will be randomized

Under the terms of the agreement, InSite grants exclusive rights to Bioceutica to commercialize AzaSite for ocular bacterial infection in Argentina, Chile, Paraguay and Uruguay. Bioceutica will also

The Care II trial began in February at St Vincent’s Hospital in Melbourne, Australia, and, so far, has led to successful implantations in 12 patients. The multi-site Care

The preclinical results also showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased

Gen-Probe expects to enroll approximately 7,000 women in the study. Actual enrollment, however, may vary based on the prevalence of cervical disease among women in the trial. The

Gross proceeds to the company are expected to be approximately $5.3 million. In the purchase agreement, Nordic Biotech Opportunity Fund, an affiliate of Nordic Biotech, the company’s largest

Under the agreement, in exchange for exclusive worldwide commercial rights to Gvax, Takeda will pay Cell Genesys an upfront payment of $50 million and additional milestone payments totaling

The study is designed to evaluate the anti-tumor effect and safety/tolerability of liposomal paclitaxel (LEP-ETU). The study will target enrolling 35 patients in five centers with histologically or